Hemogenyx Pharmaceuticals

06/19/2024

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler talked with Proactive about the company's recent operations update. In the...

04/25/2024

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) chair Marc Feldmann, in the company’s final results statement, described the year as a “period was a...

03/13/2024

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) Dr Vladislav Sandler joins Proactive's Stephen Gunnion after the pre-clinical stage biopharmaceutical...

06/20/2023

🌟 Witness the cutting-edge innovation of as they revolutionize drug development!Their groundbreaking methods and technologies are saving lives by creating new and effective medicines. Join the journey of scientific discovery and hope! 🚀

https://lnkd.in/eBCnyMdv

08/10/2022

One of America's Top Bone Marrow Transplant and Oncology Doctors Joins Hemogenyx Pharmaceuticals as Medical Director

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Dr Koen van Besien as Medical Director.

07/13/2022

11/23/2021

Hemogenyx Pharmaceuticals is hiring Cell Therapy Manufacturing Associates.

10/28/2021

Hemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom Laboratory

The Wall Street Journal news department was not involved in the creation of this content. PRESS RELEASE Hemogenyx Pharmaceuticals PLC Announces Lease of New York Mink Building Custom Laboratory October 18, 2021 LONDON, UK / ACCESSWIRE / October 18, 2021 / Hemogenyx Pharmaceuticals has signed a lease...

10/13/2021

Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement (the "Agreement") with the global biopharmaceutical company Eli Lilly and Company ("Lilly"). Under this Agreement, Lilly grants the Company an exclusive worldwide licence to certain intellectual property developed by Lilly ("IP") related to a CDX bispecific antibody ("CDX" or the "Licensed Product") for all uses, including the treatment of acute myeloid leukemia ("AML") and other blood cancers.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that it has signed a licence agreement with the global biopharmaceutical company Eli Lilly and Company.

09/04/2021

We are pleased to announce that a further patent application entitled MONOCLONAL ANTIBODIES TO HUMAN FLT3/FLK2 RECEPTOR PROTEIN has been approved and issued by the United States Patent and Trademark Office.

“…The issue of this patent is of considerable significance for the Company because it protects the IP for both CDX and HEMO-CART-T product candidates…”

U.S. Approval of Monoclonal Antibody Patent 07:00:08 02 Sep 2021 - HEMOGENYX PHARMACEUTICALS PLC - News article - Regulatory News Service